home  novelion skip to main content content enter your keywords search top menu contact us about novelionleadership team news aegerion pharmaceuticals products  pipeline physician resourcesglobal medical information expanded access program clinical programs grants  iis eu payment disclosures eu payment disclosures  eu payment disclosures  eu payment disclosures  eu payment disclosures careersemployee voices search jobs investors search about novelionleadership team news aegerion pharmaceuticals products  pipeline physician resourcesglobal medical information expanded access program clinical programs grants  iis eu payment disclosures eu payment disclosures  eu payment disclosures  eu payment disclosures  eu payment disclosures careersemployee voices search jobs investors contact us dena living with generalized lipodystrophy i look forward to studying genetics in college and using my experiences to help others we aspire to be a leader in rare diseases find out more employee voices at novelion therapeutics and our subsidiary aegerion pharmaceuticals we seek to develop new standards of care for individuals living with rare diseases we depend on the commitment ideas and actions of each individual employee to advance patient care and a create sustainable future for our organization andrés treviño senior director government affairs aegerion pharmaceuticals see what inspired them view all development pipeline our pipeline status of selected key development programs as of november  represents ongoing phase of development does not correspond to initiation or completion of a particular phase phase  phase  phase  approved aegerion products juxtapid® lomitapide homozygous familial hypercholesterolemia hofh in adults myalept® metreleptin generalized lipodystrophy gl metreleptin partial lipodystrophy pl novelion products zuretinol leber congenital amaurosis lca zuretinol retinitis pigmentosa rp  click here for juxtapid® lomitapide full us prescribing information including boxed warning for the risk of hepatotoxicity  click here for myalept® metreleptin full us prescribing information including boxed warning for the risk of antimetreleptin antibodies with neutralizing activity and risk of lymphoma  plan to submit maa for metreleptin in eu to treat gl and a subset of pl learn more recent press releases may   novelion therapeutics reports first quarter  financial results read more april   metreleptin and lipodystrophy data presented at the annual meeting of the endocrine society read more march   novelion therapeutics appoints mark corrigan md to board of directors read more march   novelion therapeutics reports preliminary fourth quarter  full year  financial results read more view all home  novelion skip to main content content enter your keywords search top menu contact us about novelionleadership team news aegerion pharmaceuticals products  pipeline physician resourcesglobal medical information expanded access program clinical programs grants  iis eu payment disclosures eu payment disclosures  eu payment disclosures  eu payment disclosures  eu payment disclosures careersemployee voices search jobs investors search about novelionleadership team news aegerion pharmaceuticals products  pipeline physician resourcesglobal medical information expanded access program clinical programs grants  iis eu payment disclosures eu payment disclosures  eu payment disclosures  eu payment disclosures  eu payment disclosures careersemployee voices search jobs investors contact us dena living with generalized lipodystrophy i look forward to studying genetics in college and using my experiences to help others we aspire to be a leader in rare diseases find out more employee voices at novelion therapeutics and our subsidiary aegerion pharmaceuticals we seek to develop new standards of care for individuals living with rare diseases we depend on the commitment ideas and actions of each individual employee to advance patient care and a create sustainable future for our organization andrés treviño senior director government affairs aegerion pharmaceuticals see what inspired them view all development pipeline our pipeline status of selected key development programs as of november  represents ongoing phase of development does not correspond to initiation or completion of a particular phase phase  phase  phase  approved aegerion products juxtapid® lomitapide homozygous familial hypercholesterolemia hofh in adults myalept® metreleptin generalized lipodystrophy gl metreleptin partial lipodystrophy pl novelion products zuretinol leber congenital amaurosis lca zuretinol retinitis pigmentosa rp  click here for juxtapid® lomitapide full us prescribing information including boxed warning for the risk of hepatotoxicity  click here for myalept® metreleptin full us prescribing information including boxed warning for the risk of antimetreleptin antibodies with neutralizing activity and risk of lymphoma  plan to submit maa for metreleptin in eu to treat gl and a subset of pl learn more recent press releases may   novelion therapeutics reports first quarter  financial results read more april   metreleptin and lipodystrophy data presented at the annual meeting of the endocrine society read more march   novelion therapeutics appoints mark corrigan md to board of directors read more march   novelion therapeutics reports preliminary fourth quarter  full year  financial results read more view all home  novelion skip to main content content enter your keywords search top menu contact us about novelionleadership team news aegerion pharmaceuticals products  pipeline physician resourcesglobal medical information expanded access program clinical programs grants  iis eu payment disclosures eu payment disclosures  eu payment disclosures  eu payment disclosures  eu payment disclosures careersemployee voices search jobs investors search about novelionleadership team news aegerion pharmaceuticals products  pipeline physician resourcesglobal medical information expanded access program clinical programs grants  iis eu payment disclosures eu payment disclosures  eu payment disclosures  eu payment disclosures  eu payment disclosures careersemployee voices search jobs investors contact us dena living with generalized lipodystrophy i look forward to studying genetics in college and using my experiences to help others we aspire to be a leader in rare diseases find out more employee voices at novelion therapeutics and our subsidiary aegerion pharmaceuticals we seek to develop new standards of care for individuals living with rare diseases we depend on the commitment ideas and actions of each individual employee to advance patient care and a create sustainable future for our organization andrés treviño senior director government affairs aegerion pharmaceuticals see what inspired them view all development pipeline our pipeline status of selected key development programs as of november  represents ongoing phase of development does not correspond to initiation or completion of a particular phase phase  phase  phase  approved aegerion products juxtapid® lomitapide homozygous familial hypercholesterolemia hofh in adults myalept® metreleptin generalized lipodystrophy gl metreleptin partial lipodystrophy pl novelion products zuretinol leber congenital amaurosis lca zuretinol retinitis pigmentosa rp  click here for juxtapid® lomitapide full us prescribing information including boxed warning for the risk of hepatotoxicity  click here for myalept® metreleptin full us prescribing information including boxed warning for the risk of antimetreleptin antibodies with neutralizing activity and risk of lymphoma  plan to submit maa for metreleptin in eu to treat gl and a subset of pl learn more recent press releases may   novelion therapeutics reports first quarter  financial results read more april   metreleptin and lipodystrophy data presented at the annual meeting of the endocrine society read more march   novelion therapeutics appoints mark corrigan md to board of directors read more march   novelion therapeutics reports preliminary fourth quarter  full year  financial results read more view all aegerion pharmaceuticals inc nasdaqaegr quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinanceaegerion pharmaceuticals incnasdaqaegradd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   aegerion pharmaceuticals inc  public nasdaqaegr   watch this stock    after hours    nov  pm est   nasdaq realtime data  disclaimer currency in usd range       week    open      vol  avg  mkt cap m pe      divyield      eps  shares m beta  inst own  news relevance date all news for aegerion pharmaceuticals inc » subscribe advertisement key stats and ratios q sep   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  main st ste cambridge ma united states  map phone fax external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry pharmaceuticals  nec more from factset » description aegerion pharmaceuticals inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases it operates through pharmaceuticals segment its products include lomitapide and metreleptin lomitapide is a small molecule microsomal triglyceride transfer protein mtp inhibitor lomitapide received marketing approval under the brand name juxtapid lomitapide capsules from the united states food and drug administration fda as an adjunct to a lowfat diet and other lipidlowering treatments it also received marketing authorization for lomitapide in the european union eu under the brand name lojuxta lomitapide hard capsules lojuxta as a treatment for hofh in adults metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor metreleptin is marketed in the united states under the brand name myalept metreleptin for injection myalept more from reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service add transaction  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancecreate new portfoliomarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   add you need to sign in to your google account to access your portfolio google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service aegerion pharmaceuticals inc options by expiration  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancemore resultsaegerion pharmaceuticals incnasdaqaegradd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   view options by expiration layout stacked   straddle aegr  pm est disclaimer advertisement highlighted options are in the money option data delayed by  minutes google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service aegerion pharmaceuticals inc private company information  bloomberg july    am et biotechnology company overview of aegerion pharmaceuticals inc snapshot people company overview aegerion pharmaceuticals inc develops and commercializes therapies for patients with debilitating rare diseases in the united states the company’s products include juxtapid lomitapide capsules an adjunct to a lowfat diet and other lipidlowering treatments including lowdensity lipoprotein lowdensity lipoprotein cholesterol total cholesterol apolipoprotein b and nonhighdensity lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia hofh and lojuxta lomitapide hard capsule for the treatment of hofh in adults its products also comprise myalept metreleptin a recombinant analogue of human leptin indicated as an adjunct to diet as replaceme aegerion pharmaceuticals inc develops and commercializes therapies for patients with debilitating rare diseases in the united states the company’s products include juxtapid lomitapide capsules an adjunct to a lowfat diet and other lipidlowering treatments including lowdensity lipoprotein lowdensity lipoprotein cholesterol total cholesterol apolipoprotein b and nonhighdensity lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia hofh and lojuxta lomitapide hard capsule for the treatment of hofh in adults its products also comprise myalept metreleptin a recombinant analogue of human leptin indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy the company distributes its products directly to patients and other purchasers through a specialty pharmacy aegerion pharmaceuticals inc was founded in  and is headquartered in cambridge massachusetts as of november   aegerion pharmaceuticals inc operates as a subsidiary of novelion therapeutics inc detailed description one main streetsuite cambridge ma united statesfounded in  employees phone  fax  wwwaegerionca key executives for aegerion pharmaceuticals inc ms barbara y chan president and chief accounting officer age  ms carolina alarco president of international mr eric curtis president of us commercial mr remi a menes chief commercial officer age  dr john j orloff md executive vice president and head of research  development age  compensation as of fiscal year  aegerion pharmaceuticals inc key developments aegerion pharmaceuticals inc presents at boston ceo conference may  pm may   aegerion pharmaceuticals inc presents at boston ceo conference may  pm venue four season boston  boylston street boston ma  united states speakers carolina alarco president of international aegerion pharmaceuticals files form  dec   aegerion pharmaceuticals inc has announced that it has filed a form  with the securities and exchange commission to voluntarily deregister its common stock  par value per share under the securities exchange act of  as amended aegerion pharmaceuticals enters into agreement in principle to settle class action shareholder lawsuit dec   novelion therapeutics inc announced that on december   aegerion pharmaceuticals entered into an agreement in principle to settle all claims in the class action shareholder lawsuit pending in the united states district court for the district of massachusetts the agreement provides for an aggregate settlement payment by or on behalf of aegerion of  million the company expects  million of the settlement will be funded by aegerion’s insurance proceeds and  will be funded by aegerion the settlement would include the dismissal of all claims against aegerion and the named individuals in the class action litigation without any liability or wrongdoing attributed to them the settlement remains subject to further documentation court approval and other customary conditions including aegerion’s right to terminate the settlement in the event an agreed upon percentage of class members do not participate similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact aegerion pharmaceuticals inc please visit wwwaegerionca company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close aegerion pharmaceuticals inc company information  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › pharmaceutical companies › aegerion pharmaceuticals inc print share aegerion pharmaceuticals inc address aegerion pharmaceuticals inc one main street suite  cambridge ma contact detailsphone  website wwwaegerioncomcareers wwwaegerioncomaboutuscareershtm drugs associated with aegerion pharmaceuticals incaegerion pharmaceuticals inc manufactures markets andor distributes more than  drugs in the united states medications listed here may also be marketed under different names in different countries nonus country and region specific information is not available on this page brandgeneric name average user rating juxtapid generic name lomitapide class miscellaneous antihyperlipidemic agents na myalept generic name metreleptin class miscellaneous metabolic agents na latest drug information updates vosevi vosevi sofosbuvir  velpatasvir  voxilaprevir is a singletablet regimen for the treatment of adults withnerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with earlytremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of adult patients withbevyxxa bevyxxa betrixaban is an oral oncedaily factor xa inhibitor anticoagulant for the extendeddurationrituxan hycela rituxan hycela rituximab and hyaluronidase human is a subcutaneous monoclonal antibody and hyaluronidasebaxdela baxdela delafloxacin is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin more drug information updates drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide aegr stock quote  aegerion pharmaceuticals inc  bloomberg markets error could not add to watchlist x  watchlist aegerion pharmaceuticals inc aegrus acquired aegrus was acquired by nvlncn usd volume  before its here its on the bloomberg terminal learn more volume  current pe ratio ttm  earnings per share usd ttm  market cap usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later there are currently no press releases for this ticker please check back later profile aegerion pharmaceuticals inc is a biopharmaceutical company the company researches smallmolecule therapeutics for cardiovascular and metabolic disease aegerions product candidates limit secretion of cholesterol and triglycerides address  main streetsuite cambridge ma united states phone  website wwwaegerioncom executives barbara y chan vpchief acctg officer benjamin harshbarger ben acting general counsel amanda murphy associate dirinvestor relations show more aegerion pharmaceuticals  novelion skip to main content content enter your keywords search top menu contact us about novelionleadership team news aegerion pharmaceuticals products  pipeline physician resourcesglobal medical information expanded access program clinical programs grants  iis eu payment disclosures eu payment disclosures  eu payment disclosures  eu payment disclosures  eu payment disclosures careersemployee voices search jobs investors search about novelionleadership team news aegerion pharmaceuticals products  pipeline physician resourcesglobal medical information expanded access program clinical programs grants  iis eu payment disclosures eu payment disclosures  eu payment disclosures  eu payment disclosures  eu payment disclosures careersemployee voices search jobs investors contact us aegerion pharmaceuticals aegerion pharmaceuticals is an indirect subsidiary of novelion therapeutics in this section leadership team news aegerion pharmaceuticals home  about novelion  aegerion pharmaceuticals aegerion pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases marketed products juxtapid®juxtapid® lomitapide capsules is a prescription medicine used along with diet and other lipidlowering treatments including lowdensity lipoprotein ldl apheresis where available in adults with homozygous familial hypercholesterolemia hofh to reduce ldl “bad” cholesterol total cholesterol a protein that carries bad cholesterol in the blood apolipoprotein b and nonhighdensity lipoprotein cholesterol nonhdlc studies have not been conducted to tell us whether juxtapid can help prevent problems from high cholesterol such as heart attack stroke death or other health problems studies have also not been conducted to tell us whether juxtapid is safe for use in people with high cholesterol who do not have hofh including those with heterozygous familial hypercholesterolemia hefh visit site myalept®myalept metreleptin is a leptin replacement therapy used with a doctorrecommended diet to treat problems caused by not having enough leptin leptin deficiency in people with generalized lipodystrophy it is not known if myalept is safe and effective when used to treat problems complications caused by partial lipodystrophy or to treat liver disease including nonalcoholic steatohepatitis nash myalept should not be used to treat people with hivrelated lipodystrophy or people with metabolic disease including diabetes mellitus and hypertriglyceridemia without signs or symptoms of congenital or acquired generalized lipodystrophy visit site important safety information warning risk of hepatotoxicity juxtapid can cause elevations in transaminases in the juxtapid clinical trial   of the  patients treated with juxtapid had at least one elevation in alanine aminotransferase alt or aspartate aminotransferase ast ≥x upper limit of normal uln there were no concomitant clinically meaningful elevations of total bilirubin international normalized ratio inr or alkaline phosphatase juxtapid also increases hepatic fat with or without concomitant increases in transaminases the median absolute increase in hepatic fat was  after both  and  weeks of treatment from  at baseline measured by magnetic resonance spectroscopy hepatic steatosis associated with juxtapid treatment may be a risk factor for progressive liver disease including steatohepatitis and cirrhosis measure alt ast alkaline phosphatase and total bilirubin before initiating treatment and then alt and ast regularly as recommended during treatment adjust the dose of juxtapid if the alt or ast are ≥x uln discontinue juxtapid for clinically significant liver toxicity because of the risk of hepatotoxicity juxtapid is available only through a restricted program under a risk evaluation and mitigation strategy rems called the juxtapid rems program  please see additional important safety information for juxtapid within the us full prescribing information important safety information warning risk of antimetreleptin antibodies with neutralizing activity and risk of lymphoma antimetreleptin antibodies with neutralizing activity have been identified in patients treated with myalept the consequences are not well characterized but could include inhibition of endogenous leptin action andor loss of myalept efficacy worsening metabolic control andor severe infection have been reported test for antimetreleptin antibodies with neutralizing activity in patients with severe infections or loss of efficacy during myalept treatment contact aegerion at  for neutralizing antibody testing  tcell lymphoma has been reported in patients with acquired generalized lipodystrophy both treated and not treated with myalept carefully consider the benefits and risks of treatment with myalept in patients with significant hematologic abnormalities andor acquired generalized lipodystrophy  because of these risks associated with the development of antimetreleptin antibodies that neutralize endogenous leptin andor myalept and the risk for lymphoma myalept is available only through a restricted program under a risk evaluation and mitigation strategy rems called the myalept rems program please see additional important safety information for myalept within the us full prescribing information company search results x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states search results for “aegro” news companies videos pictures no search results match the term aegro some suggestions  make sure all words are spelled correctly  try different words that mean the same thing  enter fewer words aegerion pharmaceuticals inc  nasdaqaegr  stock quote  news  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street aegerion pharmaceuticals inc aegr follow    nasdaq  health care nov    pm est prev close  open  day lowhigh     wk lowhigh    volume m avg volume k exchange nasdaq shares outstanding m market cap m eps  pe ratio na div  yield na na trade with jim cramer  days free latest news aegerion pharmaceuticals inc and qlt inc complete merger transaction qlt to change name to novelion therapeutics inc aegerion pharmaceuticals juxtapid® lomitapide capsules for the treatment of homozygous familial hypercholesterolemia hofh receives pricing authorization in japan aegerion pharmaceuticals announces third quarter  financial results company records  million in total net product sales nov    pm edt aegerion pharmaceuticals juxtapid® lomitapide capsules approved in japan for the treatment of homozygous familial hypercholesterolemia hofh sep    pm edt aegerion pharmaceuticals observes familial hypercholesterolemia awareness day sep    am edt aegerion pharmaceuticals appoints remi menes as chief commercial officer sep    am edt  stocks insiders love right now insiders at these companies are scooping up shares of their own stock lately sep    pm edt  stocks under  making big up moves when a stock makes a largepercentage move it is often just the start of a new major trend  a trend that can lead to huge profits aug    am edt aegerion pharmaceuticals announces second quarter  financial results aug    pm edt aegerion pharmaceuticals announces cost reduction plans company announces revision to lomitapide exus strategy and reduction in global workforce jul    pm edt  stocks under  set to soar these under stocks are within range of triggering breakout trades jun    pm edt wall street loses gains after feds unsurprising june call the results of the federal reserves june meeting were not a surprise the central bank left rates unchanged just as wall street expected jun    pm edt stocks turn lower after yellen expresses confidence in us economy stocks give back gains wednesday afternoon as federal reserve chair janet yellen expresses her confidence in the strength of the us economy jun    pm edt aegerion pharmaceuticals aegr stock surges on qlt merger aegerion pharmaceuticals aegr stock is soaring after the company agreed to merge with fellow biopharmaceutical company qlt qlti jun    pm edt wall street rises as it awaits fed crude comes off lows stocks hold gains by midmorning wednesday as investors await news on interest rates from the federal reserve jun    am edt stock futures hold gains as industrial production falls stock futures signal a wall street rebound on wednesday after four days of losses as investors await news from the federal reserve jun    am edt qlt aegerion merge two troubled biotechs normally investors get excited when two biotech companies announce a merger the exception is when the merger is more about desperation than transformation jun    am edt aegerion pharmaceuticals and qlt inc agree to strategic merger jun    am edt aegerion pharmaceuticals grants stock options under inducement program jun    pm edt  stocks under  to trade for big profits when a stock makes a largepercentage move it is often just the start of a new major trend  a trend that can lead to huge profits may    am edt aegerion pharmaceuticals announces first quarter  financial results may    pm edt shareholder alert levi  korsinsky llp announces the commencement of an investigation into possible breaches of fiduciary duty by certain officers and directors of aegerion inc levi  korsinsky announces it has commenced an investigation of aegerion inc may    pm edt aegerion pharmaceuticals announces preliminary agreements in principle with doj and sec related to ongoing investigations may    am edt aegerion pharmaceuticals to announce first quarter  financial results on monday may  may    am edt aegerion pharmaceuticals grants stock options under inducement program may    am edt aegerion pharmaceuticals grants stock options under inducement program apr    pm edt  stocks under  set to soar these stocks trading for less than  a share look poised to break out and trade higher from current levels mar    am edt aegerion pharmaceuticals observes world lipodystrophy day mar    am edt interesting aegr call options for may th investors in aegerion pharmaceuticals inc saw new options begin trading this week for the may th expiration at stock options channel our yieldboost formula has looked up and down the aegr options chain for the new may th contracts and identified the following call contract of particular interest mar    am edt tradeideas aegerion pharmaceuticals aegr is todays strong on high relative volume stock tradeideas llc identified aegerion pharmaceuticals aegr as a strong on high relative volume candidate mar    am edt next load more from our partners aegerion resumed with a neutral at jpmorgan the fly aegerion pharmaceuticals misses by  beats on revenue seekingalpha qlts qlti reports inline q loss merger in focus zacks midday gainers  losers seekingalpha healthcare  top  gainers  losers as of  am seekingalpha premarket gainers  losers as of  am seekingalpha aegerions juxtapid approved in japan for rare form of inherited high cholesterol shares up  after hours seekingalpha after hours gainers  losers seekingalpha aegerion and collegium pharma stake their claim to the biotech bull party shares up again today seekingalpha midday gainers  losers seekingalpha healthcare  top  gainers  losers as of  am seekingalpha insiderinsightscom daily round up  bbrg aat dca seekingalpha aegerion pharmaceuticals misses by  beats on revenue seekingalpha aegerion price target lowered to  from  at leerink the fly aegerion q loss narrower than expected pipeline in focus zacks trending trump just resurrected the ugly practice known as civil forfeiture for no reason walmart in focus amid horrific human trafficking incident in texas that causes nine deaths we must all stop blindly trusting in the apple iphone  it could also be viciously hacked  stocks to give as gifts earnings are back with a vengeance cramers mad money recap monday  advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers aegerion pharmaceuticals inc  federal st boston ma pharmaceutical productswholesale  mapquest aegerion pharmaceuticals inc  federal st boston ma  reviews   website menu  reservations make reservations order online tickets tickets see availability nearby directions  sponsored topics see a problem let us know legal help